The uncontrolled growth of HR+/HER2- BC is partly dependent on hormone receptors (HR) signaling pathways, involved in the transcription of growth-related genes (such as insulin growth factor I receptor, IGF-1R) and successfully inhibited by endocrine therapies (ET). This evidence concerns the gene ERBB2 and breast cancer.